IL2 and chronic graft versus host disease: Complementary or additive to low dose IL-2, the adoptive transfer of Tregs or the more specialized TFR cells could thus have a high potential in chronic GVHD, although more work is needed to determine how to best deploy TFR cells therapeutically.